Persistent Thickening Following Anti –Vascular Endothelial Growth Factor for Diabetic Macular Edema
This secondary analysis of a randomized clinical trial assesses outcomes of diabetic macular edema persisting at least 24 weeks after randomization to treatment with 2.0-mg aflibercept, 1.25-mg bevacizumab, or 0.3-mg ranibizumab.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research
More News: Avastin | Clinical Trials | Diabetes | Endocrinology | Lucentis | Opthalmology | Ranibizumab Injection